Statin non-adherence: clinical consequences and proposed solutions

Area of Science:

• Cardiology
• Pharmacology
• Public Health

Background:

• Large clinical trials confirm statin therapy reduces cardiovascular events in various patient groups.
• High-intensity statins are more effective than low-intensity ones for preventing recurrent events in acute coronary syndromes and stable coronary heart disease.
• Guidelines recommend high-intensity statin initiation for acute coronary syndrome patients, yet clinical practice falls short.

Purpose of the Study:

• To highlight the discrepancy between clinical trial evidence and real-world utilization of high-intensity statin therapy.
• To emphasize the need for improved medication utilization and persistence.
• To discuss challenges and strategies for managing statin therapy in clinical practice.

Main Methods:

• Review of clinical trial data and clinical practice observations regarding statin therapy.
• Analysis of factors contributing to suboptimal statin utilization and discontinuation.
• Exploration of treatment options for statin-intolerant patients.

Main Results:

• Despite proven efficacy, high-intensity statins are underprescribed and frequently discontinued in clinical practice.
• Perceived adverse events are a primary reason for statin discontinuation.
• A multi-stakeholder approach is required to enhance statin therapy adherence.

Conclusions:

• Coordinated efforts involving patients, providers, pharmacists, health systems, and insurers are crucial for optimizing statin therapy.
• Validated tools are needed to accurately assess statin-associated adverse events.
• Alternative statin regimens, combination therapies (e.g., ezetimibe), and newer agents (e.g., PCSK9 inhibitors) offer options for statin-intolerant patients.